Loading
Pumitamig / Durvalumab / Non Small Cell Lung Cancer (NSCLC) · Phase 3 Trial
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a prospectively registered Phase 3 trial comparing pumitamig to durvalumab as consolidation therapy following concurrent chemoradiation in unresectable stage III NSCLC, with progression-free survival as the primary outcome. No results have been posted to the registry; the study is currently recruiting.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Non-small Cell Lung Cancer (NSCLC); age from 18 Years. Intervention: Arm A. Compared with: Arm B — Active Comparator. n = 850. 259 sites across 32 countries.
This is a prospectively registered Phase 3 trial comparing pumitamig to durvalumab as consolidation therapy following concurrent chemoradiation in unresectable stage III NSCLC, with progression-free survival as the primary outcome. No results have been posted to the registry; the study is currently recruiting.
No efficacy, safety, or outcome data exist; this describes a planned trial only.
The source did not state who this applies to in practice.
This is a registered Phase 3 trial currently recruiting with no results posted; it describes a planned comparison but carries no outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07361497). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 850 participants (ESTIMATED). Conditions: Non-small Cell Lung Cancer (NSCLC). Interventions: DRUG: Pumitamig; DRUG: Durvalumab. Primary outcome measures: Progression-free survival (PFS) by blinded independent central review (BICR) (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) , Up to 3 years. Brief summary: A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.